CTIP2 Diagnostic Marker for Head and Neck Cancer

Summary

 

Technology Description

 

This technology opportunity provides a method for detecting CTIP2 or CTIP2L and for their use as biomarkers for squamous cell carcinoma. This technology can be used to develop kits for detecting SCC in a patient. The kit can include a CTIP2 and CTIP2L -specific antibody, oligonucleotides, or primers, and a chart or diagram showing biomarker expression values that are expected in the presence of SCC (or a particular stage of SCC). An increase in expression of at least 2-fold relative to a reference value for a sample negative for SCC indicates the presence of SCC in the sample obtained from the subject.

 

Features & Benefits

 

  • Provides Immunohistochemical (IHC) and PCR based approaches for improved diagnosing and staging of SCC

 

Applications

 

  • Detecting, diagnosing, and staging SCC
  • Drug development

 

Background of Invention

 

Squamous cell carcinoma (SCC) is a malignant tumor that occurs in many different organs, including the skin, lips, mouth, esophagus, head and neck, urinary bladder, prostate, lungs, breast, vagina, cervix, and ovaries. The current state diagnosing SCC requires a skin biopsy and examination under a microscope.

 

Status

 

Patented (U.S. Patent no. 8,071,815). This technology is currently available for exclusive or non-exclusive licensing.

 

Patent Information:
Tech ID:
OSU-07-69
Category(s):
Diagnostics
Contact:
Joe Christison
IP & Licensing Manager
Oregon State University
541-737-9016
joe.christison@oregonstate.edu
Inventors:
Arup Indra
Mark Leid
Joseph Abecassis
Gitali Indra
Keywords:
Biomedical
Pharmaceuticals
Diagnostic
Research Tools
© 2017. All Rights Reserved. Powered by Inteum